REG - Advanced Oncotherapy - Update re admission of Subscription Shares

Advanced OncotherapyAnnouncement

23/08/2022 15:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220823:nRSW9667Wa&default-theme=true

RNS Number : 9667W  Advanced Oncotherapy PLC  23 August 2022

23 August 2022

ADVANCED ONCOTHERAPY PLC

 

("Advanced Oncotherapy" or the "Company")

 

Update re admission of Subscription Shares

 

Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the next-generation
proton therapy system for cancer treatment, provides an update regarding the
Subscription announced on 19 August 2022.

 

Admission, due to take place tomorrow, 24 August 2022, will now comprise
4,460,000 Subscription Shares.

 

Application will be made for the remaining 1,400,000 Subscription Shares to be
admitted to trading on AIM ("Second Admission") and it is expected that Second
Admission will occur on or around 16 September 2022. The warrants relating to
the Subscription Shares being issued on Second Admission will be issued on or
around 17 September 2022.

 

Total Voting Rights

Following Admission on 24 August 2022, the Company's enlarged issued share
capital will comprise 505,831,209 Ordinary Shares, of 25 pence each
("Ordinary Shares"). The Company does not hold any Ordinary Shares in
treasury. Therefore, the total number of Ordinary Shares in the Company with
voting rights on 24 August 2022 will be 505,831,209. Upon Second Admission,
the Company's enlarged issued share capital will comprise 507,231,209
Ordinary Shares, of 25 pence each and the total number of Ordinary Shares in
the Company with voting rights on Second Admission will be 507,231,209. The
aforementioned figures may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Defined terms used in this announcement shall have the same meaning as in the
announcement of 19 August 2022 unless otherwise defined herein.

 

 

 

- ENDS -

 

 

 Advanced Oncotherapy plc                                  www.avoplc.com (http://www.avoplc.com/)
 Dr. Michael Sinclair, Executive Chairman                  Tel: +44 (0) 20 3617 8728
 Nicolas Serandour, CEO

 Allenby Capital Limited (Nomad and Joint Broker)
 Nick Athanas / Liz Kirchner (Corporate Finance)           Tel: +44 (0) 20 3328 5656

 Amrit Nahal / Matt Butlin (Sales and Corporate Broking)

 SI Capital Ltd (Joint Broker)
 Nick Emerson                                              Tel: +44 (0) 1483 413 500
 Jon Levinson                                              Tel: +44 (0) 20 3871 4066

 FTI Consulting (Financial PR & IR)                        advancedoncotherapy@fticonsulting.com
                                                           (mailto:advancedoncotherapy@fticonsulting.com)
 Simon Conway / Rob Winder                                 Tel: +44 (0) 20 3727 1000

 

 

About Advanced Oncotherapy Plc

Advanced Oncotherapy, a UK headquartered company with offices in London,
Geneva, The Netherlands and in the USA, is a provider of particle therapy with
protons that harnesses the best in modern technology. Advanced Oncotherapy's
team "ADAM," based in Geneva, focuses on the development of a proprietary
proton accelerator called, Linac Image Guided Hadron Technology (LIGHT).
LIGHT's compact configuration delivers proton beams in a way that facilitates
greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that
will enable them to treat cancer with innovative technology as well as
expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging
improvements in delivering proton therapy and actively seeks working
relationships with providers of these innovative technologies. Through these
relationships, the Company will remain the prime provider of an innovative and
cost-effective system for particle therapy with protons.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEBKNBKQBKDFFB